SEARCH

SEARCH BY CITATION

References

  • Akin, C. (2003) Multilineage hematopoietic involvement in systemic mastocytosis. Leukemia Research, 27, 877878.
  • Akin, C., Kirshenbaum, A.S., Semere, T., Worobec, A.S., Scott, L.M. & Metcalfe, D.D. (2000) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Experimental Hematology, 28, 140147.
  • Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R. & Gilliland, D.G. (2003a) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine, 348, 12011214.
  • Cools, J., Stover, E.H., Boulton, C.L., Gotlib, J., Legare, R.D., Amaral, S.M., Curley, D.P., Duclos, N., Rowan, R., Kutok, J.L., Lee, B.H., Williams, I.R., Coutre, S.E., Stone, R.M., DeAngelo, D.J., Marynen, P., Manley, P.W., Meyer, T., Fabbro, D., Neuberg, D., Weisberg, E., Griffin, J.D. & Gilliland, D.G. (2003b) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell, 3, 459469.
  • Cools, J., Quentmeier, H., Huntly, B.J., Marynen, P., Griffin, J.D., Drexler, H.G. & Gilliland, D.G. (2004) The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 103, 28022805.
  • Fleiss, J. & Cuzick, J. (1979) The reliability of dichotomous judgements: unequal numbers of judges per subject. Applied Psychological Measurement, 3, 537542.
  • Gessner, A., Mohrs, K. & Mohrs, M. (2005) Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. Journal of Immunology, 174, 10631072.
  • Gilliland, G., Cools, J., Stover, E.H., Wlodarska, I. & Marynen, P. (2004) FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. Hematology Journal, 5(Suppl. 3), S133S137.
  • Gotlib, J., Cools, J., Malone, III, J.M., Schrier, S.L., Gilliland, D.G. & Coutre, S.E. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood, 103, 28792891.
  • Griffin, J.H., Leung, J., Bruner, R.J., Caligiuri, M.A. & Briesewitz, R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences USA, 100, 78307835.
  • Kirshenbaum, A.S., Goff, J.P., Semere, T., Foster, B., Scott, L.M. & Metcalfe, D.D. (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood, 94, 23332342.
  • Klion, A.D., Noel, P., Akin, C., Law, M.A., Gilliland, D.G., Cools, J., Metcalfe, D.D. & Nutman, T.B. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood, 101, 46604666.
  • Klion, A.D., Robyn, J., Akin, C., Noel, P., Brown, M., Law, M., Metcalfe, D.D., Dunbar, C. & Nutman, T.B. (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 103, 473478.
  • Migliaccio, A.R., Rana, R.A., Sanchez, M., Lorenzini, R., Centurione, L., Bianchi, L., Vannucchi, A.M., Migliaccio, G. & Orkin, S.H. (2003) GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. Journal of Experimental Medicine, 197, 281296.
  • Musto, P., Falcone, A., Sanpaolo, G., Bodenizza, C., Perla, G., Minervini, M.M., Cascavilla, N., Dell'Olio, M., La, S.A., Mantuano, S., Melillo, L., Nobile, M., Scalzulli, P.R., Bisceglia, M. & Carella, A.M. (2004) Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leukemia and Lymphoma, 45, 12191222.
  • Pack, S.D., Karkera, J.D., Zhuang, Z., Pak, E.D., Balan, K.V., Hwu, P., Park, W.S., Pham, T., Ault, D.O., Glaser, M., Liotta, L., tera-Wadleigh, S.D. & Wadleigh, R.G. (1999) Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes and Cancer, 25, 160168.
  • Pardanani, A., Reeder, T., Li, C.Y. & Tefferi, A. (2003) Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leukemia Research, 27, 883885.
  • Pardanani, A., Brockman, S.R., Paternoster, S.F., Flynn, H.C., Ketterling, R.P., Lasho, T.L., Ho, C.L., Li, C.Y., Dewald, G.W. & Tefferi, A. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 104, 30383045.
  • Raskind, W.H., Steinmann, L. & Najfeld, V. (1998) Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia, 12, 108116.
  • Reeder, T.L., Bailey, R.J., Dewald, G.W. & Tefferi, A. (2003) Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood, 101, 19811983.
  • Spivak, J.L. (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Seminars in Hematology, 41, 15.
  • Takahashi, N., Miura, I., Saitoh, K. & Miura, A.B. (1998) Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood, 92, 47584763.
  • Tefferi, A., Schad, C.R., Pruthi, R.K., Ahmann, G.J., Spurbeck, J.L. & Dewald, G.W. (1995) Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genetics and Cytogenetetics, 83, 6164.
  • Tefferi, A., Lasho, T.L., Brockman, S.R., Elliott, M.A., Dispenzieri, A. & Pardanani, A. (2004) FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica, 89, 871873.
  • Yu, C., Cantor, A.B., Yang, H., Browne, C., Wells, R.A., Fujiwara, Y. & Orkin, S.H. (2002) Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. Journal of Experimental Medicine, 195, 13871395.
  • Zou, G. & Donner, A. (2004) Confidence interval estimation of the intraclass correlation coefficient for binary outcome data. Biometrics, 60, 807811.